Escolar Documentos
Profissional Documentos
Cultura Documentos
CIPLA Ltd
PRESENTED BY:
Agenda
Introduction SWOT : Cipla Ltd Act/ Regulations Past & Ongoing Sustainability Practices Sustainability Framework
One of the worlds largest generic companies. Over 2,000 products, 65 therapeutic categories, over 40 dosage forms. 34 state-of-the-art manufacturing facilities approved by major international regulatory agencies. Continuous innovation in R&D; over 20 world firsts. Turnover(USD)-1.4 billion having 20,000 employees. Approvals-US FDA, WHO-Geneva, MHRA-UK, TGAAustralia, SUKL-Slovak Republic, APVMA-Australia, among others
With
Cipla
Sustainability
The
Company has reduced the price of anti-AIDs and Anti-asthma drugs five times through technological advancements.
SWOT Analysis
STRENGTHS 1 Ranks #2 in the retail prescription market & has excellent distribution network 2 Large basket of 1,500 formulations; Partnered 8 leading generics companies in the US for nearly 125 projects. 3 Voluminous product portfolio having more than 200brands,few of them the leading brands. 4 Excellent process R&D skills, considered to be one of the best in the country
5
WEAKNESSES 1 Impact of IPR regime. 2 It is not present in CRAMS and BioPharmaceutical segment which are the best projected segment in the industry.
OPPORTUNITIES
SWOT
THREATS 1 Partnership related; and
2 Potential de-rating.
KEY RISK
An unfavorable court ruling in an ongoing litigation between the Government of India and Cipla regarding alleged overcharging of certain drugs could potentially pressurize the Companys bottom line.
If the cost of raw material keep on increasing due to increased pressure on Chinese companies to move to higher level drugs, companies margin will be hit drastically.
Act/ Regulations
Every company having : net worth of Rs.500 crore or more turnover of Rs.1000 crore or more net profit of Rs.5 crore or more
During any financial year is required to constitute a Corporate Social Responsibility Committee.
If the company fails to spend such amount the Board shall give in its report the reasons for the same making it a binding obligation on the Board This covers the pharmaceutical companies as well Such a company is required to spend at least two per cent of the average net profits of the company made during the three immediately preceding financial years, in pursuance of its Corporate Social Responsibility Policy
10
An Act to regulate the profession of pharmacy Persons, having no knowledge and having no education in pharmacy or pharmaceutical chemistry or pharmacology, were engaged in this profession
11
Fast pace of commercialization and globalization on all spheres of life has affected the medical as well Consumer means Any "person" who hires or ails of any services/products for a consideration which has been paid or promised or partly paid and partly promised Any fault, imperfection, short coming or inadequacy in the quality, nature and manner of performance will be covered by this act Litigations can be filed against doctors/hospitals/ companies in case of above mentioned deficiencies.
12
An act to regulate import, manufacture, distribution and sale of drugs and cosmetics
13
To provide the protection and improvement of environment To safeguard the forests and wildlife of the country The Air (prevention and Control of Pollution) Act was passed in 1981 to Control Air Pollution
14
It is illegal for a person to produce/ manufacture/ cultivate, possess, sell, purchase, transport, store, and/or consume any narcotic drug or psychotropic substance Cultivation/production/manufacture, possession, sale, purchase, transport, storage, consumption or distribution of any of the following substances such as :
15
Sustainability
16
Sustainability
17
Maintaining a modern, well-equipped effluent treatment plant at all our manufacturing facilities. Treated water from these zero discharge facilities is used for maintaining green belts around the factory premises.
Among the first companies to manufacture CFC-free inhalers, 10 years before the Montreal Protocol January 2010 deadline.
Policies have been introduced and are visibly placed to ensure compliance.
Sustainability
18
The company is committed to ensure that all employees operate in a work environment that is compliant with all relevant charters and labor regulations.
Conducting regular safety training programs, including those on behavioral safety to increase safety awareness at all working levels.
19
Provides holistic care to terminally ill cancer patients and their families free of charge. Till now the Centre has given treatment, comfort and solace to more than 7,700 patients. A Pune-based organization which runs a home for children with HIV infection.
Cipla Foundation
The company made a breakthrough in reducing the prices of cancer drugs In order to make drugs for malaria, HIV/AIDS and several neglected diseases, available at affordable prices, CIPLA works closely with several reputed non-profit organizations such as
All efforts are made to ensure that no uncontrolled products or chemicals pollute the environment.
Emergency procedures and spills kits are available on-site.
Waste
management
All waste is sent to designated sites and is tracked on a monthly basis. A separate upgraded high-hazard waste area is being built
ISO 14000 principles are being implemented in preparation for future certification.
5 million donation was made to the trust. The educational grant awarded to students in the field of engineering, medicine and pharmaceutical studies.
Launched to raise funds to enable Operation Smile SA to create awareness And provide free reconstructive surgery for children born with cleft lips and/or palates.
AdoptaSchool
Cipla Medpro, for the third time, held a fundraising event in November 2010 for the benefit of the Adopt-a-School project. The funds donated to the Peninsula School Feeding Association were allocated to seven schools and provided meals for 1 336 learners.
25
CHALLENGES
As a part of its sustainability conformance, it tries to offer medicines for the lowest possible price for all diseases from Asthma to AIDS
26
Cipla has always been associated with selling of low cost drugs globally.
Most of the challenges faced are deliberate suing by its competitors for patent infringement or for the low prices.
Past Challenges
1. INDIAN PATENTS ACT, 2005 2. BAYER PHARMACEUTICALS
27
28
The Parliament of India made key amendments to the Indian Patents Act in 2005.
Severely affected the AIDS drug being offered by Cipla.
BAYER PHARMACEUTICALS
29
German pharmaceutical giant Bayer sued Cipla for patent infringement. Low prices of cancer drug Nexavar by Cipla. 76% of the price was slashed by Cipla at 1710.
30
Refrained from setting from its own direct presence in the markets abroad.
Sells it products through partnership with local firms and established pharmaceutical companies.
31
32
Business Sustainability
seeks to create long-term shareholder value by embracing the opportunities and managing the risks that result from an organizations economic, environmental, and social responsibilities.
must meet the needs of the organization and its stakeholders today while also protecting, sustaining, and enhancing the environmental, social, and economic resources needed for the future
33
Cipla Ltd needs to enhance its probability of achieving business success and sustainability Move through several phases, during which it progressively broadens the scope of its approach
Quality
Business Business
34
Working to support broader health and development goals in developing countries, including by considering voluntary licences.
35
Affordability Investment
in R&D
Pharmaceutical
Importance
36
Develop or maintain, differential pricing offers for Developing countries. Least developed countries (LDCs) Sub-Saharan Africa
Monitor and publicly disclose basis of product scope, price , population coverage, countries, pro-poor nature, product leakage, health systems strengthening overall commitment of stakeholders.
37
Increase levels of investment in research and development for medicines and vaccines for diseases disproportionat ely affecting developing countries.
Work in partnership with others where appropriate, including through public private partnerships.
Develop approaches to intellectual property management that optimise the benefits of R&D, including through sharing knowledge
38
should:
Work with stakeholders in countries of operation to ensure access to medicines initiatives are integrated with national systems and priorities
Explore opportunities for production in developing countries, including through wholly owned subsidiaries
39
Work with third party verifiers where appropriate, to measure, and report on, impact.
Take steps to make reports accessible to a wide range of stakeholders, including key stakeholders in developing countries.
40
Thank you